Telacebec is under clinical development by Qurient and currently in Phase II for Pulmonary Tuberculosis. According to GlobalData, Phase II drugs for Pulmonary Tuberculosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Telacebec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Telacebec overview

Telacebec (Q-203) is under development for the treatment of tuberculosis including MDR (multidrug-resistant)/XDR (extensively drug-resistant)/TDR (totally drug resistant)-TB, and buruli ulcer. It is administered through oral route. It is developed based on phenomic screen technology. Q-203 acts by targeting cytochrome bc1 complex of MTB.

The therapeutic candidate was under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Qurient overview

Qurient is a biotechnology company. It develops drugs for unmet medical needs of atopic diseases and cancer. The company offers pipeline products that include Q301, a topical leukotriene inhibitor for the treatment of atopic dermatitis; Telacebec (Q203), a Cyt bc1 Inhibitor for combating mycobacterium associated tuberculosis infection; and Q702, an Axl/Mer/CSF1R triple kinase inhibitor for the treatment of drug resistant non-small cell lung cancer and other cancer types. Qurient in-licensed Q702 from Max Planck Innovation and Lead Discovery Center. It is also advancing its pre-clinical pipeline that includes a topical 5-lipoxygenase inhibitor to treat allergic and atopic diseases; and selective CDK7 inhibitors to treat cancer. Qurient is headquartered in Seongnam, Gyeonggi, South Korea.

For a complete picture of Telacebec’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.